US 12,480,120 B2
Hippo and dystrophin complex signaling in cardiomyocyte renewal
James F. Martin, Pearland, TX (US); Yuka Morikawa, Houston, TX (US); Todd Ryan Heallen, Houston, TX (US); and John P. Leach, Pearland, TX (US)
Assigned to Baylor College of Medicine, Houston, TX (US); and Texas Heart Institute, Houston, TX (US)
Filed by Baylor College of Medicine, Houston, TX (US); and Texas Heart Institute, Houston, TX (US)
Filed on Apr. 11, 2024, as Appl. No. 18/633,108.
Application 18/633,108 is a continuation of application No. 17/931,270, filed on Sep. 12, 2022, granted, now 11,981,895.
Application 17/931,270 is a continuation of application No. 17/096,260, filed on Nov. 12, 2020, granted, now 11,459,565, issued on Oct. 4, 2022.
Application 17/096,260 is a continuation of application No. 16/544,209, filed on Aug. 19, 2019, abandoned.
Application 16/544,209 is a continuation of application No. 16/164,550, filed on Oct. 18, 2018, abandoned.
Application 16/164,550 is a continuation of application No. 15/642,200, filed on Jul. 5, 2017, granted, now 10,119,141, issued on Nov. 6, 2018.
Application 15/642,200 is a continuation of application No. 15/102,593, granted, now 9,732,345, issued on Aug. 15, 2017, previously published as PCT/US2014/069349, filed on Dec. 9, 2014.
Claims priority of provisional application 61/913,715, filed on Dec. 9, 2013.
Prior Publication US 2024/0279661 A1, Aug. 22, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/713 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 31/713 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2320/30 (2013.01); C12N 2740/15043 (2013.01); C12N 2750/14143 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A synthetic isolated nucleic acid comprising:
(i) a sequence comprising SEQ ID NO:12 or a derivative nucleic acid comprising at least 90% identity to SEQ ID NO:12, and
(ii) an antisense sequence of SEQ ID NO:12 or the derivative nucleic acid,
wherein, when the sequence and the antisense sequence are hybridized together to form a duplex structure, the sequence and the antisense sequence are separated by a loop structure.